cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.4q7r4z
title: Occurrence Download

description: A dataset containing 46477 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Africa",
 "DatasetKey is EOD – eBird Observation Dataset",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Month is one of (July, August, September, October, November, December)",
 "OccurrenceStatus is Present",
 "TaxonKey is Scolopacidae",
 "Year 2024-2025"
 ]
}

 The dataset includes 46477 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0080997-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31023469
title: Supplementary Material for: Lung function impairment after mild SARS-CoV-2 infection in previously healthy individuals

description: Background The physiological basis for dyspnea, a hallmark of Post-COVID Syndrome (PCS), remains poorly understood. 

Methods In this analysis of the prospective, multicenter, population-based, longitudinal COVIDOM study, we studied 936 previously healthy adults assessed ≥6 months after a mostly mild, PCR-confirmed SARS-CoV-2 infection. Participants underwent comprehensive pulmonary function testing including spirometry, body plethysmography, diffusing capacity for carbon monoxide (DLCO), and airwave oscillometry (AOS). Dyspnea was assessed by questionnaires (mMRC≥1 / MDP-A1 domain≥1). We performed cross-sectional and longitudinal analyses for lung function in relation to both dyspnea and a previously defined PCS severity score (PCS-S).

Results Between 11/2020 and 05/2023, we examined 936 previously healthy COVIDOM participants (median age 37 [IQR 28-51], 56% female). Dyspnea prevalence increased significantly with PCS severity (low PCS-S: 19.3%; intermediate PCS-S: 53.8%; high PCS-S: 81.8%; p&lt;0·001). Women suffered more frequently from dyspnea and PCS. Small airway dysfunction, as indicated by abnormal R5-20Hz or AX5Hz measures, tended to be more frequent in participants with high PCS severity and dyspnea compared to those with low PCS and no dyspnea (37% vs. 25%, p=0.058) with corresponding R5-20Hz of 0.03 [0.01-0.07] vs. 0.01 [0-0.03] kPa·L⁻¹·s⁻¹ (p&lt;0.01). Longitudinally, however, none of the baseline or follow-up lung function parameters, including measures of SAD, differed between participants with persistent dyspnea and those who became asymptomatic.

Conclusion Oscillometry-derived R5-R20Hz differed significantly between dyspneic PCS patients and controls. The high frequency of SAD and the absence of longitudinal improvement might indicate the potential clinical relevance of SAD assessment, despite its only numeric differences between PCS severity groups.
DOI: 10.6084/m9.figshare.31023469.v1
title: Supplementary Material for: Lung function impairment after mild SARS-CoV-2 infection in previously healthy individuals

description: Background The physiological basis for dyspnea, a hallmark of Post-COVID Syndrome (PCS), remains poorly understood. 

Methods In this analysis of the prospective, multicenter, population-based, longitudinal COVIDOM study, we studied 936 previously healthy adults assessed ≥6 months after a mostly mild, PCR-confirmed SARS-CoV-2 infection. Participants underwent comprehensive pulmonary function testing including spirometry, body plethysmography, diffusing capacity for carbon monoxide (DLCO), and airwave oscillometry (AOS). Dyspnea was assessed by questionnaires (mMRC≥1 / MDP-A1 domain≥1). We performed cross-sectional and longitudinal analyses for lung function in relation to both dyspnea and a previously defined PCS severity score (PCS-S).

Results Between 11/2020 and 05/2023, we examined 936 previously healthy COVIDOM participants (median age 37 [IQR 28-51], 56% female). Dyspnea prevalence increased significantly with PCS severity (low PCS-S: 19.3%; intermediate PCS-S: 53.8%; high PCS-S: 81.8%; p&lt;0·001). Women suffered more frequently from dyspnea and PCS. Small airway dysfunction, as indicated by abnormal R5-20Hz or AX5Hz measures, tended to be more frequent in participants with high PCS severity and dyspnea compared to those with low PCS and no dyspnea (37% vs. 25%, p=0.058) with corresponding R5-20Hz of 0.03 [0.01-0.07] vs. 0.01 [0-0.03] kPa·L⁻¹·s⁻¹ (p&lt;0.01). Longitudinally, however, none of the baseline or follow-up lung function parameters, including measures of SAD, differed between participants with persistent dyspnea and those who became asymptomatic.

Conclusion Oscillometry-derived R5-R20Hz differed significantly between dyspneic PCS patients and controls. The high frequency of SAD and the absence of longitudinal improvement might indicate the potential clinical relevance of SAD assessment, despite its only numeric differences between PCS severity groups.
DOI: 10.6084/m9.figshare.31023472
title: Supplementary Material for: A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma

description: Introduction: Despite recent advances in treatment for unresectable hepatocellular carcinoma (uHCC), median overall survival (OS) in the first-line setting across immune-based combination therapies has plateaued at 16–24 months. Evaluation of potentially more potent therapies is warranted. We report results of the first prospective phase 1b study of lenvatinib (multi-kinase inhibitor) + nivolumab (anti-PD-1 antibody) for treating advanced uHCC.
Methods: This open-label study was conducted in Japan among adults (≥20 years) with histologically/cytologically confirmed HCC. Patients received monotherapy-approved doses of either 8 mg (body weight &lt;60 kg) or 12 mg (body weight ≥60 kg) oral lenvatinib once daily + 240 mg intravenous nivolumab every 2 weeks (days 1 and 15) in 4-week cycles. Part 1 planned to enroll 6 patients to evaluate the tolerability of lenvatinib+nivolumab. Part 2 evaluated safety and preliminary anti-tumor activity. Primary endpoints were dose-limiting toxicities (DLTs; part 1 only) and safety. Secondary endpoints were objective response rate (ORR) and pharmacokinetics of lenvatinib and nivolumab. Additional exploratory endpoints (including OS and progression-free survival; part 2 only) were assessed. 
Results: No DLT was observed among patients (n = 6) in part 1. Treatment-related adverse events (TRAEs) were observed in all patients (n = 30) in part 1 and 2. The most common TRAEs were palmar-plantar erythrodysesthesia syndrome (60%), dysphonia (53.3%), and decreased appetite (50.0%). Distributions of lenvatinib AUC(0-t) were similar to those observed for lenvatinib in HCC previously and were within the distributions of AUC(0-τ) observed with lenvatinib monotherapy in the REFLECT trial. ORR by mRECIST per investigator review was 66.7% in part 1 and 79.2% in part 2. In part 2, median progression-free survival was 9.07 months by mRECIST per investigator review, and median OS was 26.94 months.
Conclusion: Lenvatinib+nivolumab was well-tolerated and had encouraging anti-tumor activity in patients with advanced uHCC in this phase 1b study.
DOI: 10.6084/m9.figshare.31023472.v1
title: Supplementary Material for: A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma

description: Introduction: Despite recent advances in treatment for unresectable hepatocellular carcinoma (uHCC), median overall survival (OS) in the first-line setting across immune-based combination therapies has plateaued at 16–24 months. Evaluation of potentially more potent therapies is warranted. We report results of the first prospective phase 1b study of lenvatinib (multi-kinase inhibitor) + nivolumab (anti-PD-1 antibody) for treating advanced uHCC.
Methods: This open-label study was conducted in Japan among adults (≥20 years) with histologically/cytologically confirmed HCC. Patients received monotherapy-approved doses of either 8 mg (body weight &lt;60 kg) or 12 mg (body weight ≥60 kg) oral lenvatinib once daily + 240 mg intravenous nivolumab every 2 weeks (days 1 and 15) in 4-week cycles. Part 1 planned to enroll 6 patients to evaluate the tolerability of lenvatinib+nivolumab. Part 2 evaluated safety and preliminary anti-tumor activity. Primary endpoints were dose-limiting toxicities (DLTs; part 1 only) and safety. Secondary endpoints were objective response rate (ORR) and pharmacokinetics of lenvatinib and nivolumab. Additional exploratory endpoints (including OS and progression-free survival; part 2 only) were assessed. 
Results: No DLT was observed among patients (n = 6) in part 1. Treatment-related adverse events (TRAEs) were observed in all patients (n = 30) in part 1 and 2. The most common TRAEs were palmar-plantar erythrodysesthesia syndrome (60%), dysphonia (53.3%), and decreased appetite (50.0%). Distributions of lenvatinib AUC(0-t) were similar to those observed for lenvatinib in HCC previously and were within the distributions of AUC(0-τ) observed with lenvatinib monotherapy in the REFLECT trial. ORR by mRECIST per investigator review was 66.7% in part 1 and 79.2% in part 2. In part 2, median progression-free survival was 9.07 months by mRECIST per investigator review, and median OS was 26.94 months.
Conclusion: Lenvatinib+nivolumab was well-tolerated and had encouraging anti-tumor activity in patients with advanced uHCC in this phase 1b study.
DOI: 10.15468/dl.pawsh3
title: Occurrence Download

description: A dataset containing 7682 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (Tanzania, United Republic of, Kenya, Ethiopia, Rwanda, Uganda, Burundi)",
 "OccurrenceStatus is Present",
 "TaxonKey is Impatiens"
 ]
}

 The dataset includes 7682 records from 80 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0080998-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31023475
title: Supplementary Material for: Efficacy of Faricimab in Neovascular Age-Related Macular Degeneration: A Single-Arm Systematic Review and Meta-Analysis

description: Purpose: To evaluate the efficacy of faricimab in neovascular age-related macular degeneration (nAMD). 
Methods: This systematic review and meta-analysis was performed according to the PRISMA guidelines to identify studies assessing faricimab in nAMD. Primary outcomes included visual acuity, central macular thickness (CMT), and dry macula rate. Secondary outcomes included macular status, central choroidal thickness (CCT), and complications. A random-effects model was used to calculate pooled mean with 95% confidence intervals. 
Results: Out of the 365 studies identified, 21 studies were included, comprising a total sample size of 1864 eyes of 1791 patients. Post-operatively, there was a statistically significant improvement in corrected distance visual acuity (CDVA) (SMD: -0.122, 95% P = 0.039) and CMT (SMD: -3.672, P = 0.010). Similarly, there was a significant improvement in the rate of dry macula at the final follow-up visit (event rate: 0.529; P &lt; 0.05). For the secondary outcomes, there was a statistically significant improvement in CCT (SMD: -0.199, P = 0.026) and in the rate of macular exudates (0.452, P &lt; 0.05), specifically intraretinal fluid (0.140, P &lt; 0.05) and subretinal fluid (0.271, P &lt; 0.05). Complications secondary to faricimab injections included hemorrhagic pigment epithelial detachment (PED) with a rate of 0.120 (P &lt; 0.05) and retinal pigment epithelium (RPE) tear with a rate of 0.025 (P &lt; 0.05). 
Conclusions: The use of faricimab injection in patients with nAMD is safe and effective, resulting in significant improvements in a myriad of visual measures and OCT parameters.
DOI: 10.6084/m9.figshare.31023475.v1
title: Supplementary Material for: Efficacy of Faricimab in Neovascular Age-Related Macular Degeneration: A Single-Arm Systematic Review and Meta-Analysis

description: Purpose: To evaluate the efficacy of faricimab in neovascular age-related macular degeneration (nAMD). 
Methods: This systematic review and meta-analysis was performed according to the PRISMA guidelines to identify studies assessing faricimab in nAMD. Primary outcomes included visual acuity, central macular thickness (CMT), and dry macula rate. Secondary outcomes included macular status, central choroidal thickness (CCT), and complications. A random-effects model was used to calculate pooled mean with 95% confidence intervals. 
Results: Out of the 365 studies identified, 21 studies were included, comprising a total sample size of 1864 eyes of 1791 patients. Post-operatively, there was a statistically significant improvement in corrected distance visual acuity (CDVA) (SMD: -0.122, 95% P = 0.039) and CMT (SMD: -3.672, P = 0.010). Similarly, there was a significant improvement in the rate of dry macula at the final follow-up visit (event rate: 0.529; P &lt; 0.05). For the secondary outcomes, there was a statistically significant improvement in CCT (SMD: -0.199, P = 0.026) and in the rate of macular exudates (0.452, P &lt; 0.05), specifically intraretinal fluid (0.140, P &lt; 0.05) and subretinal fluid (0.271, P &lt; 0.05). Complications secondary to faricimab injections included hemorrhagic pigment epithelial detachment (PED) with a rate of 0.120 (P &lt; 0.05) and retinal pigment epithelium (RPE) tear with a rate of 0.025 (P &lt; 0.05). 
Conclusions: The use of faricimab injection in patients with nAMD is safe and effective, resulting in significant improvements in a myriad of visual measures and OCT parameters.
DOI: 10.15468/dl.k7uw6f
title: Occurrence Download

description: A dataset containing 27600 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is one of (USA.29_1, USA.45_1)",
 "OccurrenceStatus is Present",
 "TaxonKey is one of (Gaillardia pulchella, Cirsium mohavense, Prosopis glandulosa, Penstemon palmeri, Parkinsonia florida, Keckiella, Larrea tridentata, Chilopsis linearis, Baileya multiradiata, Cleomaceae, Lotus utahensis, Lupinus argenteus, Eriogonum fasciculatum, Tetradymia canescens, Eriogonum palmerianum, Asclepias speciosa, Agastache urticifolia, Peritoma lutea, Penstemon speciosus, Monardella odoratissima, Eriophyllum lanatum, Eriogonum umbellatum)",
 "Year 2015-2025"
 ]
}

 The dataset includes 27600 records from 53 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005394-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qzb6m5
title: Occurrence Download

description: A dataset containing 238 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-75.45732 10.94494,-76.38043 9.85846,-76.07 9.34381,-75.54718 8.9762,-75.46549 8.7393,-75.30211 8.20014,-74.99169 8.29,-74.83648 8.00409,-74.6731 7.66099,-74.57507 7.16268,-74.33 6.80324,-74.0114 7.09732,-73.52126 7.33423,-73.34971 7.46493,-73.10464 8.08578,-73.34154 8.6086,-73.0883 9.34381,-72.81056 10.13621,-72.58182 10.6917,-72.00182 11.25537,-70.84182 11.79452,-70.86632 12.0641,-71.25027 12.5134,-71.88745 12.6196,-72.45112 12.01509,-73.04746 11.70466,-73.79901 11.58213,-74.33817 11.54945,-74.48521 11.13283,-74.93451 11.41058,-75.45732 10.94494))",
 "TaxonKey is Anopheles Meigen, 1818"
 ]
}

 The dataset includes 238 records from 12 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054463-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ydx82r
title: Occurrence Download

description: A dataset containing 404 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "Geometry POLYGON((115.19758 38.55012,135.26101 38.55012,135.26101 54.02258,115.19758 54.02258,115.19758 38.55012))",
 "TaxonKey is Vitis amurensis Rupr."
 ]
}

 The dataset includes 404 records from 12 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054464-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.8uskdq
title: Occurrence Download

description: A dataset containing 11312 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ixodes ricinus Linnaeus, 1758"
 ]
}

 The dataset includes 11312 records from 180 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054465-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.2tbgc9
title: Occurrence Download

description: A dataset containing 70 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "Geometry POLYGON((115.4822 38.56047,134.98932 38.56047,134.98932 53.66362,115.4822 53.66362,115.4822 38.56047))",
 "TaxonKey is Zanthoxylum schinifolium Siebold & Zucc."
 ]
}

 The dataset includes 70 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054466-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.bm3e84
title: Occurrence Download

description: A dataset containing 2448 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, SIGANIDAE, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 158165944, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 211762827, Siganidae, 205994216, 210218730, Siganidae, Siganidae, Siganidae, 212269192, 205830969, Siganidae, Siganidae, Siganidae, Siganidae, 197287173, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 209459682, 209454833, Siganidae, Siganidae, 204357598, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 203894533, Siganidae, 209458962, Siganidae, Siganidae, Siganidae, 212282618, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae Richardson 1837, Siganidae Richardson, 1837, Siganidae Richardson, 1837, Siganidae Richardson, 1837, 161428146, Siganidae Richardson, 1837, Siganidae Richardson, 1837, Siganidae Richardson 1837, Cavisomidae Meyer, 1932, Scatophagidae Gill, 1883, Scatophagidae, Scatophagidae, Callionymidae, Gobiidae)",
 "BasisOfRecord is one of (Specimen, Human Observation, Observation, Living Specimen, Machine Observation, Literature Occurrence)",
 "Geometry POLYGON((109.5 20.15,117.25 20.15,117.25 24,109.5 24,109.5 20.15))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 2448 records from 25 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054468-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.nwbd9x
title: Occurrence Download

description: A dataset containing 22162 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Helictochloa versicolor (Vill.) Romero Zarco, Avena scheuchzeri subsp. pretuniana Arc., Avena versicolor Vill., Avena versicolor var. villarsiana St.-Yves, Avenastrum versicolor (Vill.) Fritsch, Avenochloa pretutiana (Arcang.) Holub, Avenochloa versicolor (Vill.) Holub, Avenula scheuchzeri Dumort. ex E.Salisb., 1947, Avenula versicolor (Vill.) M.Laínz, Avenula versicolor subsp. versicolor, Danthorhiza versicolor (Vill.) Ten., Helictotrichon versicolor (Vill.) Pilg., Helictotrichon versicolor (Vill.) Schult. & Schult.f.)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen, Specimen, Machine Observation)"
 ]
 }
 },
 "Continent is Europe",
 "Year is greater than or equal to 1900",
 "Year is less than or equal to 2024",
 "Month is greater than or equal to January",
 "Month is less than or equal to December"
 ]
}

 The dataset includes 22162 records from 95 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054467-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mfnq2s
title: Occurrence Download

description: A dataset containing 114 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-77.00278 38.86752,-77.00472 38.86776,-77.01 38.86181,-77.01667 38.85817,-77.01946 38.85289,-77.02408 38.84173,-77.02881 38.8254,-77.02869 38.81934,-77.02693 38.81934,-77.016 38.82134,-77.01643 38.82698,-77.01503 38.82898,-77.00891 38.83693,-77.00678 38.84221,-77.00678 38.84689,-77.00654 38.8515,-77.00448 38.85708,-77.00265 38.86139,-77.00278 38.86752))",
 "TaxonKey is Plantae"
 ]
}

 The dataset includes 114 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054470-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.60656/82302042c7734eb4
title: Custom collection of categorize, classification, drizzle, ice water content, liquid water content, and model data from Potenza on 13 Jul 2009
DOI: 10.15468/dl.xqgkue
title: Occurrence Download

description: A dataset containing 2448 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, SIGANIDAE, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 158165944, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 211762827, Siganidae, 205994216, 210218730, Siganidae, Siganidae, Siganidae, 212269192, 205830969, Siganidae, Siganidae, Siganidae, Siganidae, 197287173, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 209459682, 209454833, Siganidae, Siganidae, 204357598, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, 203894533, Siganidae, 209458962, Siganidae, Siganidae, Siganidae, 212282618, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae, Siganidae Richardson 1837, Siganidae Richardson, 1837, Siganidae Richardson, 1837, Siganidae Richardson, 1837, 161428146, Siganidae Richardson, 1837, Siganidae Richardson, 1837, Siganidae Richardson 1837, Cavisomidae Meyer, 1932, Scatophagidae Gill, 1883, Scatophagidae, Scatophagidae, Callionymidae, Gobiidae)",
 "BasisOfRecord is one of (Specimen, Human Observation, Observation, Living Specimen, Machine Observation, Literature Occurrence)",
 "Geometry POLYGON((109.5 20.15,117.25 20.15,117.25 24,109.5 24,109.5 20.15))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 2448 records from 25 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054471-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.